Text Size
Trial record 6 of 7 for:    Open Studies | "Cardiac Output, Low"
Previous Study | Return to List | Next Study

Levosimendan in High Risk Patients Undergoing Cardiac Surgery (HSR-LEVO)

This study is currently recruiting participants.
Verified May 2013 by Università Vita-Salute San Raffaele
Sponsor:
Information provided by:
Università Vita-Salute San Raffaele
ClinicalTrials.gov Identifier:
NCT00994825
First received: October 7, 2009
Last updated: June 5, 2013
Last verified: May 2013
History of Changes
  Purpose

Low cardiac output syndrome (LCOs) is a serious complication in critically ill patients or those undergoing major surgery, resulting in multiple organ damage with significant in-hospital and long-term morbidity and mortality, as well as prolonged hospital stay. In this setting the mortality rate is distressingly high despite improvements in intensive care treatment, but survivors have an acceptable quality of life.


Condition Intervention Phase
Low Cardiac Output Syndrome
 Drug: Levosimendan
Drug: placebo
 Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Levosimendan to Reduce Mortality in High Risk Cardiac Surgery Patients. A Multicentre Randomized Controlled Trial

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Università Vita-Salute San Raffaele:

Study Start Date: November 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
"Soluvit" ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
 Drug: placebo
"Soluvit" ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%
Other Name: placebo
Experimental: Levosimendan Drug: Levosimendan
Other Name: simdax

  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Written informed consent
  • Age > 18 years
  • Perioperative myocardial dysfunction

Exclusion Criteria:

  • Previous unusual response to levosimendan or soluvit or any of their components
  • Inclusion in other randomised controlled studies in the previous 30 days
  • Levosimendan administration in the previous 30 days
  • Parkinson's disease
  • Emergency operation
  • Kidney or liver transplant
  • Liver cirrhosis (Child B or C)
  • Decision to use ECMO (ECMO already started or planned)
  • Do not resuscitate patient
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00994825

Contacts
Contact: giovanni landoni, MD landoni.giovanni@hsr.it

Locations
Italy
Ospedale San Raffaele di Milano, Italy Recruiting
Milano, Italy, 20132
Contact: giovanni landoni, MD            
Ospedale San Gerardo di Monza Not yet recruiting
Monza, Italy
Sponsors and Collaborators
Università Vita-Salute San Raffaele
Investigators
Study Chair: Alberto Zangrillo, MD Vita-Salute University of Milano
  More Information

Additional Information:
italian association of cardiothoracic anesthesiologists  This link exits the ClinicalTrials.gov site
italian society of anesthesiologists  This link exits the ClinicalTrials.gov site

Publications:

ClinicalTrials.gov Identifier: NCT00994825     History of Changes
Other Study ID Numbers: GO/URC/ER/mm 768/DG
Study First Received: October 7, 2009
Last Updated: June 5, 2013
Health Authority: Italy: Ministry of Health

Keywords provided by Università Vita-Salute San Raffaele:
levosimendan
cardiac surgery
cardiac anesthesia
 mortality
survival
inotropic drugs

Additional relevant MeSH terms:
Cardiac Output, Low
Heart Diseases
Cardiovascular Diseases
Signs and Symptoms
Simendan
Anti-Arrhythmia Agents
Cardiovascular Agents
Therapeutic Uses
 Pharmacologic Actions
Cardiotonic Agents
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Vasodilator Agents
Protective Agents
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 17, 2013